Reduced Risk Of Breast Cancer Recurrence Seen With Zometa


In a study published in the New England Journal of Medicine, it was found that Zometa (zoledronic acid) reduces risk of breast cancer recurrence in premenopausal women. It was found that by adding Zometa to post-surgery hormone therapy there was a reduced risk of breast cancer return or death of 36% compared to hormone therapy alone.

The study is from the Austrian Breast & Colorectal Cancer Study Group (ABCSG). This ABCSG Trial 12 was a large, randomized, Phase III clinical trial that included more than 1,800 premenopausal women with early-stage breast cancer and fewer than ten axillary positive nodes. After undergoing curative surgery and goserelin treatment to suppress their ovaries, the women were randomly assigned into one of four study groups: (1) anastrozole plus Zometa; (2) anastrozole alone; (3) tamoxifen plus Zometa; (4) tamoxifen alone. The treatment phase of the study lasted three years. The women were followed for an additional two years.

The results demonstrated that the addition of Zometa to hormone therapy significantly prolonged both disease-free survival (36% reduction) and recurrence-free survival (35% reduction).


There were fewer deaths (16 vs 26) among those who received Zometa rather than hormone therapy alone.

Zometa is the most widely prescribed drug for prevention of bone complications due to bone metastases. It has been used in more 2.7 million patients worldwide. Zometa is indicated for patients with multiple myeloma and documented bone metastases from solid tumors in conjunction with standard antineoplastic therapy.

"The possible return of breast cancer is a major concern among women who've undergone surgery to remove their tumors. We anticipate that this publication in The New England Journal of Medicine will provide oncologists with evidence regarding an additional treatment regimen to further help reduce the risk of breast cancer recurrence, or even death, for premenopausal women with hormone-sensitive breast cancer," said lead investigator Michael Gnant, MD, of the Medical University of Vienna.

Gnant, M. et al. Adjuvant Endocrine Therapy Plus Zoledronic Acid in Premenopausal Women With Early Breast Cancer: First Efficacy Results from ABCSG-12. N Engl J Med. 2009 Feb 12; VOLUME / PAGE 2. Mundy, GR, et al.